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Abstract
Background: Monocytes are a major component of the tumor microenvironment (TME) in pancreatic ductal
adenocarcinoma (PDAC). However, the complex interactions between tumor cells and monocytes and their role in
tumor invasion have not been fully established.
Methods: To specifically test the impact of interaction on invasive potential two PDAC cell lines PaTu8902 and
CFPAC-1 were selected on their ability to form invasive adhesions, otherwise known as invadopodia and invade in
a spheroid invasion assay.
Results: Interestingly when the PDAC cells were co-cultured with undifferentiated THP1 monocyte-like cells
invadopodia formation was significantly suppressed. Moreover, conditioned media of THP1 cells (CM) was also able
to suppress invadopodia formation. Further investigation revealed that both tissue inhibitor of metalloproteinase
(TIMP) 1 and 2 were present in the CM. However, suppression of invadopodia formation was found that was
specific to TIMP2 activity.
Conclusions: Our findings indicate that TIMP2 levels in the tumour microenvironment may have prognostic value
in patients with PDAC. Furthermore, activation of TIMP2 expressing monocytes in the primary tumour could present
a potential therapeutic opportunity to suppress cell invasion in PDAC.
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Background
Pancreatic ductal adenocarcinoma (PDAC) is a devastat-
ing disease characterised by an aggressive biological
tumour behaviour leading to a high mortality rate [1].
The invasive character of PDACs leads to a rapid pro-
gression of the disease [2]. In order to invade the sur-
rounding tissue or to create distant metastases, cancer
cells need to break through the basement membrane
and degrade the extracellular matrix. One identified
strategy is to utilise actin-rich membrane protrusions
called invadopodia [3] that can degrade extracellular
matrix. Initiating mechanisms to suppress such forma-
tion is a potential therapeutic target [4]. Unlike
podosomes - which are present in normal myeloid cells
– invadopodia are specific for invasive cancer cells [5].
The primary purpose of invadopodia is the targeted se-
cretion of matrix metalloproteases (MMPs) to degrade
the extracellular matrix (ECM) [6]. Membrane-type 1
metalloprotease (MT1-MMP, also known as MMP14),
MMP9 and MMP2 have been identified as the most im-
portant MMPs in invadopodia functionality [7, 8].
MMPs can be inhibited by tissue inhibitors of metallo-
proteinases (TIMPs). Of the four TIMPs [9, 10], TIMP1
and 2 are the best-studied. TIMP1 has a relatively low
affinity for membrane-bound MMPs [11] whereas
TIMP2 is a strong inhibitor of MT1-MMP [12]. Very lit-
tle is known about the effects of TIMPs on invadopodia
formation, although one study in human breast cancer
cells suggested TIMP2 is specifically able to decrease the
formation of invadopodia [13].
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In recent years, the tumour microenvironment (TME)
has become of major interest to researchers and has
recently been suggested to play a specific role in influen-
cing the formation of invadopodia [14]. Around 90% of
the PDAC mass are stromal cells, only 10% are
carcinoma cells [15]. The main components of the TME
are cancer-associated fibroblasts (CAF) and tumour-
associated macrophages (TAMs). The pancreatic TME is
rich in TAMs but undifferentiated monocytes [16] are
also present at detectable levels. The interaction between
monocytes / macrophages and the tumor cells is com-
plex with both pro- and anti-tumorigenic effects re-
ported [17].
This study aimed to establish whether an interaction
between PDAC cells and undifferentiated monocyte-like
cells presented pro- or anti-tumorigenic responses.
Methods
Cell culture
Patu8902 and Capan2 were obtained from “Deutsche
Sammlung von Mikroorganismen und Zellkulturen
GmbH” [DSMZ], Germany), Capan1 and MiaPaCa2
were kindly provided by Prof. H. Kocher at Barts Cancer
Institute, UK. The human breast cancer cell line MDA-
MB-231 was purchased from ATCC. All these cells were
maintained in Dulbecco’s modified Eagle’s media
(DMEM, Sigma Aldrich UK) supplemented with 10% v/v
fetal bovine serum (FBS) and 1mM penicillin/strepto-
mycin. CFPAC-1 cells (kindly provided by Dr. A. Pessina
at Universita degli studi di Milano, Italy) were cultured
in Iscove’s modified Eagle’s media (IMEM, Sigma Al-
drich UK) supplemented with 10% v/v fetal bovine
serum (FBS) and 1mM penicillin/streptomycin. Colo-
357 (kindly provided by Prof. Michalski University Hos-
pital Heidelberg, Germany) and AsPC1 (kindly provided
by Dr. Stéphanie Kermorgant, Barts Cancer Institute,
UK) were cultured in Roswell Park Memorial Institute-
1640 (RPMI-1640, Sigma Aldrich UK) media supple-
mented with 10% v/v FBS with 1 mM penicillin/strepto-
mycin. THP-1 cells (obtained from the European
Collection of Authenticated Cell Cultures catalogue
number 88081201) were tagged with enhanced green
fluorescent protein (eGFP) using lentiviral vector tech-
nique as described before [18]. Cells were maintained in
RPMI-1640 media supplemented with 10% v/v FBS with
1 mM penicillin/streptomycin. For inhibitor treatment
cells were incubated with 10mM GM6001 as previously
described [19]. The cell lines have not recently been au-
thenticated. All cell lines were regularly screened for
mycoplasma contamination.
THP-1-conditioned media (CM)
THP-1 cells were seeded in serum-free, antibiotic-free
RPMI media at a density of 200,0000 cells/ml and incu-
bated at 37 °C and a 5% carbon dioxide (CO2) atmos-
phere. After 24 h, the cell suspension was centrifuged at
1500 rpm at room temperature for 10 min. CM was ei-
ther directly used for experiments (fresh CM), stored at
− 20 °C and rewarmed to 37 °C (frozen CM) or heat-
inactivated at 95 °C for 10 mins (boiled CM).
Antibodies
Anti-TIMP1 antibody (D10E6) produced in rabbit was
purchased from Cell Signalling Technology, U.S.A., anti-
TIMP2 antibody produced in rabbit antibody
(SAB4502972) was purchased from Sigma. Anti-MT1-
MMP, Anti-MMP2 and Anti-MMP9 antibody were pro-
duced in rabbit and purchased from Cell Signalling
Technology, U.S.A.. Anti-GAPDH antibody was pur-
chased from Millipore, U.S.A.
Table 1 Tumor characteristics and invadodopodia formationa of tested cell lines
Cell line Tumor entity Source of tumour cells Invadopodia formation
PaTu8902 PDAC Primary tumor yes
CFPAC-1 PDAC Liver metastasis yes
MiaPaCa-2 PDAC Primary tumor inconsistent
CAPAN-2 PDAC Primary tumor inconsistent
Panc-1 PDAC Primary tumor inconsistent
CAPAN-1 PDAC Liver metastasis no
PaTu8988-T PDAC Liver metastasis no
PaTu8988-S PDAC Liver metastasis no
Colo357 PDAC Lymph node metastasis no
AsPC1 PDAC Ascites no
MDA-MB-231b Breast cancer Pleural effusion yes
PDAC Pancreatic Ductal Adenocarcinoma
aActive invadopodia formation was defined as cortactin puncta corresponding with black dots on the gelatin
bMDA-MB-231 cells are well known for producing robust invadopodia formation and were used as a positive control
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Invadopodia assay
For the invadopodia assays, the QCM™ Gelatin Invado-
podia Assay (Red) (Chemicon® / Millipore) was used.
Briefly, coverslips were inverted onto poly-L-lysine in
deionized water for 20 min at room temperature (RT).
The slides were then washed with phosphate buffered
saline (PBS) three times before incubation with glutaral-
dehyde: PBS for 15 min at RT. After washing three times
with PBS, each coverslip was placed on gelatin in PBS in
a 1:5 ratio of fluorescently-labelled - unlabelled gelatin
and incubated for 10 min at RT and subsequently
washed in PBS three times. The. Patu8902 and CFPAC-
1 cells were detached using non-enzymatic Cell Dissoci-
ation Solution (Sigma Aldrich UK), resuspended in
DMEM F-12 growth media (10% FBS, 1 mM penicillin/
streptomycin) and seeded onto the prepared coverslips.
For co-culture experiments cells were seeded in the
presence of control media (serum-free RPMI media and
DMEM-F12 media in a 1:1 ratio), in the presence of
THP1-CM (frozen CM mixed with DMEM-F12 media
with 10% FBS and 1% P/S in a 1:1 ratio) or in the pres-
ence of 50,000 THP1 cells. Alternatively, PDAC cells
were co-cultured with THP1 cells for 24 h prior to dis-
sociation and seeding on prepared coverslips.
Spheroid assay
Spheroids were formed in black walled 96-wells clear
black round bottom ultra-low attachment spheroid mi-
croplates (Corning). First, 1000 cancer cells were seeded
in 200 μl DMEM F-12 growth media (10% FBS, 1 mM
penicillin/streptomycin), Then, the was centrifuged at
200 g for 8 min at room temperature. Cells were then
cultured at 37 °C with 5% CO2 for 72 h. After spheroid
assembly was achieved, 170ul medium was removed by
multichannel pipetting. A collagen mixture was prepared
on ice with a final concentration of 1.3 mg/ml rat tail
collagen I (Corning). A collagen matrix of 100 μl was
then added to each well with a multichannel pipette.
The spheroid plate was then incubated at 37 °C with 5%
CO2 for 2 h. A 1:1 mixture of serum-free RPMI and
DMEM-F12 with 10% FBS and 1mM penicillin/strepto-
mycin was then added on top of the collagen matrix to
initiate the assay. Brightfield images were obtbained with
a 4x objective at 0 h and 48 h, respectively.
MTT viability assay
For the MTT assay, Patu8902 cells in full growth media
(DMEM supplemented with 10% FBS and 1mM penicil-
lin/streptomycin) were seeded in a triplicates in three 96
well plates. Plate 1 was used as a treatment-naïve con-
trol. Growth medium in plate 2 and 3 were removed
from the wells and replaced with a) normal growth
medium (DMEM supplemented with 10% FBS and 1
mM penicillin/streptomycin), b) DMEM supplemented
with 10% FBS and 1mM penicillin/streptomycin mixed
with serum-free DMEM (1:1), c) (DMEM supplemented
with 10% FBS and 1mM penicillin/streptomycin mixed
with frozen and rewarmed THP1-CM (1:1), d) DMEM
supplemented with 10% FBS and 1mM penicillin/
streptomycin containing rTIMP2 (50 ng/ml). The MTT
assay is performed after 24 h (plate 1, control), 72 h
(plate 2) and 120 h (plate 3). Cells were washed twice
with sterile PBS and incubated with MTT:DMEM solu-
tion (500 μg/ml) for 4 h. The MTT:DMEM was removed
and DMSO added, the plates were then incubated at
37 °C for 10 min. Absorbance was measured at a wave-
length of 562 nm using a Nanodrop.
Western blot
Serum-free THP-1 conditioned media (CM), serum-free
RPMI containing recombinant TIMP1 and TIMP2
(expressed in CHO cells Sigma Aldrich UK) in various
concentrations ranging from 5 to 6000 ng/ml, respect-
ively, and serum-free RPMI control media, respectively,
were filled in a Spin-X® UF concentrators (Spin-X UF 6
10 K MWCO, Corning) and centrifuged at 4000 rpm for
18min at RT. Subsequently, gel sample buffer was added
to the concentrated CM and the sample was boiled at
90 °C for 3 min. Equal amounts of protein were electro-
phoresed on 10% sodium dodecyl sulfate (SDS)-poly-
acrylamide gels then transferred to nitrocellulose
membranes as described elsewhere [20]. Nitrocellulose
were incubated with primary antibodies using the rec-
ommended concentrations and horseradish peroxidase
(HRP)-conjugated secondary antibodies (Dako Ltd). Cell
lysates were seeded in 6-well plates and cultured for 24
h. Lysates were generated when cells were 70–80% con-
fluent. First, cells were washed with PBS and then lysates
were generated with 100 μl NP40 based lysis buffer per
well. Lysates were scrapped and centrifuged at 13000 x g
(See figure on previous page.)
Fig. 1 PaTu8902 and CFPAC-1 cells exhibit robust invadopodia activity. a Pancreatic ductal adenocarcinoma (PDAC) cell lines were analysed for
seeded on fluorescent gelatin for 24 h fixed and stained for cortactin and DAPI. Cortactin puncta corresponding with black dots on the gelatin
were considered active invadopodia. b Quantification of degradation per field of view for (a), MDA-MB-231 cells were also seeded on fluorescent
gelatin for 24 h and the degradation per field of view calculated as a positive control. c PaTu8902, CFPAC-1 and PaTu8988-S cell lysates were
blotted for MT1-MMP. PaTu8902 and CFPAC-1 show high levels of MT1-MMP expression whereas PaTu8988-S shows no MT1-MMP expression. d
Western blot of PaTu8902 and CFPAC-1 cell lysates showing high levels of MMP9 expression. e Western blot of PaTu8902 and CFPAC-1: indicating
no expression of TIMP2
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for 15 min at 4 °C. The Supernatant was then transferred
to an Eppendorf tube and boiled for 3 min at 95 °C in 6x
laemmli buffer. Samples were stored at − 20 °C. Equal
amounts of protein were then electrophoresed on 7.5%
SDS-polyacrylamide gels and immunoblotting was per-
formed as described above.
Determination of rTIMP1 and rTIMP2 concentrations
Since there are no comparable studies using rTIMP1
and 2, respectively, in an invadopodia model, the ap-
proximate concentration had to be estimated. Physio-
logic TIMP1 and 2 levels, respectively, range between 5
and 1000 ng/ml [21, 22]. In a second step, CM and
RPMI control media containing either TIMP1 or TIMP2
in various concentrations ranging from 5 to 6000 ng/ml
was concentrated as described above and immuno-
blotted for TIMP1 and TIMP2, respectively. Autoradio-
graphs were quantified using ImageJ software. The
concentration of TIMP2 in the conditioned medium was
calculated from the intensity values of the TIMP2 signal
in the conditioned medium against the intensity values
for recombinant TIMP2 signal. TIMP1 and TIMP2
levels in the CM varied between the experiments and
were ranging between 5 and 50 ng/ml. Therefore, these
concentrations were used for the later rTIMP1 and
rTIMP2 experiments.
Micro Array
THP1 CM was screened for proteins using the RayBio® C-
Series Human Cytokine Antibody Array C5 (RayBiotech
Norcross, USA) according to the manufacturer’s protocol.
Immunofluorescence
Following 24 h-incubation, cells were fixed and stained
as previously described. Cells were stained for F-actin
(Alexa fluor 488-conjugated phalloidin, Invitrogen),DAPI
(Sigma Aldrich UK) and cortactin (Anti-Cortactin (p80/
85) Antibody, clone 4F11; Millipore).
Image analysis
Images were analysed using ImageJ 1.51 h (National Insti-
tutes of Health, USA). For gelatine degradation analysis,
the total amount of degradation per image was measured
in a total of 10 images per tested condition. The amount
of degradation was computed automatically using ImageJ.
For the spheroid assay, the invasive front was determined
as the area of all cells invading from the spheroid. The in-
vasive front was calculated as the area of the invading cells
relative to the size of the spheroid after 48 h. Relative
spheroid growth was determined by measuring the total
area of the spheroids at 0 h and 48 h, respectively.
Statistical analyses
For data collection and statistical analysis, Microsoft Excel
(Microsoft, Redmond, USA) and Prism 5.0 (GraphPad
Software, La Jolla, CA, USA) were used. To test for signifi-
cant differences, the two-tailed Student’s t-tests was used.
Data are presented as mean ± standard error of the mean
(SEM). A difference was considered significant at p < 0.05.
Results
Pancreatic cancer cells produce invadopodia
As compared to the well-described characteristics of
invadopodia formation in breast cancer cells, especially
in the cell line MDA-MB 231 [23, 24], less is known
about invadopodia in PDAC cells [25]. We screened 10
different PDAC cell lines for invadopodia formation and
compared the findings with MDA-MB 231 breast cancer
cells (Table 1). Our screen revealed that PaTu8902 and
CFPAC-1 constitutively form a large number of invado-
podia. To confirm our observations, invadopodia areas
of matrix degradation were co-localised with cortactin-
positive puncta as a marker of invadopodia (Fig. 1a). We
found that PDAC cells require longer incubation times
than previously reported for breast cancer cells [23] to
generate quantifiable degradation activity and thus quan-
tification of activity was based on the total area of gelatin
degradation per field of view. PaTu8902 and CFPAC-1
(See figure on previous page.)
Fig. 2 Invadopodia formation can be suppressed by co-culturing PaTu8902 and CFPAC-1 cells with monocyte-like cells. a Representative images
from a PaTu8902 invadopodia assay where the cells were either incubated with control medium (control), incubated with THP1 conditioned
medium (THP1-CM), or were cultured with THP1 cells during the invadopodia assay (THP1-DC), or cultured with THP1 cells prior to the
invadopodia assay (THP1-PC). For the THP1-PC condition, growth medium (GM) containing the THP1 cells was evacuated and washed with PBS. b
Quantification of degradation per field of view for experimental conditions described above (a). c Representative images from a CFPAC-1
invadopodia assay where the cells were either incubated with control medium (control), incubated with THP1 conditioned medium (THP1-CM),
or were cultured with THP1 cells during the invadopodia assay (THP1-DC), or cultured with THP1 cells prior to the invadopodia assay (THP1-PC). d
Quantification of degradation per field of view for experimental conditions described above (c). e Representative images from a PaTu8902
spheroid assay where the cells were either incubated with control medium (control) or incubated with THP1 conditioned medium (THP1-CM) at
0 h and 48 h. f Quantification of spheroid invasion for experimental conditions described above (e). g Quantification of relative spheroid growth
after 48 h for experimental conditions described above (e). h Representative images from a Panc1 spheroid assay where the cells were either
incubated with control medium (control) or incubated with THP1 conditioned medium (THP1-CM) at 0 h and 48 h. i Quantification of spheroid
invasion for experimental conditions described above (h). j Quantification of relative spheroid growth after 48 h for experimental conditions
described above (i). In all cases **** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, * = p < 0.05. Experiments were repeated three times
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cells revealed high levels of degradative activity (Fig. 1b).
Both invadopodia-forming cell lines PaTu8902 and
CFPAC-1 expressed MT1-MMP whereas PaTu8988-S
did not (Fig. 1c). CFPAC-1 and PaTu8902 were further
tested for MMP9 (positive, Fig. 1d) and MMP2 (no ex-
pression, data not shown). Neither CFPAC-1 nor
PaTu8902 were expressing TIMP2 (Fig. 1e).
Monocyte-like cells co-culture suppresses invadopodia
driven matrix degradation
We performed a number of different co-culture experi-
ments with eGFP-tagged THP1 cells (THP1; a commonly
used cell line model for undifferentiated monocyte-like
cells) and PaTu8902 cells (Fig. 2a&b) or CFPAC-1 cells
(Fig. 2c&d). Either the PDAC cells and THP1 cells were
cultured together prior to the invadopodia assay, or PDAC
cells and THP1 cells were cultured together during the
invadopodia assay, or conditioned medium from THP1
cells was added to the PDAC cells during the invadopodia
assay. In all co-culture conditions, gelatin degradation was
reduced compared to control in both cell lines (Fig. 2a-d).
The suppressive effect of THP-1 CM was confirmed in
the spheroid invasion assay. Since CFPAC-1 is not form-
ing adequate spheroids, PANC-1 cells were used instead
(Fig. 2e,f,h&i). THP-1 CM did not alter proliferation and
spheroid growth (Fig. 2g&j).
Tissue inhibitor of metalloproteinases 1 and 2 are
secreted by THP1 monocyte-like cells
Given that exposure to conditioned medium was suffi-
cient to suppress invadopodia activity we explored this
phenomenon in more detail in both cell lines. The gel-
atin degradation assays were repeated using a control
condition (control media) and three different CM condi-
tions. To assess the nature of the inhibitory factor, CM
was either boiled, used immediately after collection
(fresh CM) or freeze/thawed. Incubation of cells with
fresh or freeze/thawed CM significantly reduced invado-
podia formation whereas incubation with boiled CM was
unable to significantly reduce activity compared to con-
trol cells (Fig. 3a-d). These findings suggest that the fac-
tors secreted by THP1 cells to suppress invadopodia
actively are likely to be protein based.
To further elucidate the nature of THP1 CM suppres-
sion of invadopodia activity the THP1 CM was screened
against a microarray of selected hormones and cytokines
(Fig. 3e). The only proteins detected in significant con-
centrations were RANTES, Interleukin 8 (IL-8) as well
as tissue inhibitor of metalloproteinases 1 and 2 (TIMP1
and TIMP2). Both RANTES [26] and IL-8 are suggested
to rather promote than reduce cancer cell invasion, so
we focused on the further examination of TIMP1 and
TIMP2. Initially, we validated the array by testing
whether TIMP1 (Fig. 3g) and TIMP2 (Fig. 3h) were
present in the THP1 CM compared to RPMI alone. We
then proceeded to determine the concentration of both
TIMP1 and TIMP2 in THP CM by comparing the de-
tected signal between the conditioned medium and
medium containing known concentrations of recombin-
ant TIMP1 (Fig. 3i) or TIMP2 (Fig. 3j). We were able to
establish (see methods section) that there was between 5
and 50 ng/ml of TIMP1 (Fig. 3i) and TIMP2 (Fig. 3j) in
THP1 CM.
Inhibition of invadopodia formation is driven specifically
by TIMP2
To assess the specific effects of TIMPs on invasion, the
invadopodia assays were repeated adding commercial re-
combinant TIMP1 (rTIMP1) or recombinant TIMP2
(rTIMP2), respectively at two different concentrations, 5
ng/ml and 50 ng/ml, to cover the range of likely concen-
tration in conditioned medium (Fig. 3i&j). Whilst the
presence of rTIMP1 had no impact on degradative abil-
ity (Fig. 3a&b), the presence of rTIMP2 was able to sig-
nificantly reduce gelatin degradation in the treated cells
even at a concentration of 5 ng/ml (Fig. 4a&c). More-
over, similar results were obtained when CFPAC-1 cells
were treated with rTIMP2 but not with rTIMP1
(See figure on previous page.)
Fig. 3 THP1 cells secrete TIMP1 and TIMP2. a Representative images from a PaTu8902 invadopodia assay where the cells were either incubated
with control medium, conditioned medium that had been applied fresh, boiled or freeze/thawed as indicated. b Quantification of degradation
per field of view for experimental conditions described above (a). c Representative images from a CFPAC-1 invadopodia assay where the cells
were either incubated with control medium, conditioned medium that had been applied fresh, boiled or freeze/thawed as indicated. d
Quantification of degradation per field of view for experimental conditions described above (c). e THP1 conditioned media protein micro array
(see methods for details). f concentrated samples of THP1 CM and RPMI 1640 control were immunoblotted for TIMP1 using specific antibodies. g
control media containing recombinant TIMP1 was immunoblotted in comparison to aliquots of concentrated samples of THP1 CM for TIMP1
using specific antibodies. Molecular weight markers indicated for TIMP 1 (19 kD) and TIMP 2 (24 kD). h concentrated samples of THP1 CM and
RPMI 1640 control were immunoblotted for TIMP2 using specific antibodies. Molecular weight markers indicated for TIMP 1 (19 kD) and TIMP 2
(24 kD). i control media containing recombinant TIMP1 was immunoblotted in comparison to a concentrated sample of THP1 CM using TIMP2
using specific antibodies. Molecular weight markers indicated for TIMP 1 (19 kD) and TIMP 2 (24 kD). Experiments were repeated three times. j
control media containing recombinant TIMP2 was immunoblotted in comparison to a concentrated sample of THP1 CM using TIMP2 using
specific antibodies. Note, double bands in Fig. 3j are considered dimers of the TIMP2 molecule. All experiments were repeated three times.
Molecular weight markers indicated for TIMP 1 (19 kD) and TIMP 2 (24 kD)
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(Fig. 4d-f). Our results suggest a specific inhibition of
invadopodia activity in PDAC cells exposed to low con-
centrations of TIMP2. However, we cannot rule out a
global deleterious effect of rTIMP2 exposure on cell be-
haviour. To address this issue we tested whether cells
could recover invadopodia activity if the rTIMP2 was re-
moved. As a control, responses were compared to incu-
bation with a pharmacological MMP inhibitor GM6001
which is known to transiently inhibit invadopodia forma-
tion until washed out [27] (Fig. 5a&b). Subsequently, we
tested the recovery of cells incubated with rTIMP2 for 5
h prior to removal (Fig. 5c&d). Similar results were ob-
tained when CFPAC-1 cells were examined in the same
protocol (Fig. 5e-h). Thus, the inhibition of invadopodia
activity in the presence of rTIMP2 is a specific response.
Furthermore, an MTT assay confirmed that neither
THP-1 CM nor rTIMP2 had an effect on viability and
proliferation (Table 2).>
Discussion
There is evidence suggesting there is a strong link in
some tissue types between the ability of cancer cells to
form invadopodia in vitro and their invasive potential
in vivo [28]. However, only one previous study screened
PDAC cell lines for invadopodia formation [25]. Al-
though in this case, the authors reported invadopodia
prevalence in most cell lines, this was not comparatively
quantified and degradation activity was not assessed. In-
deed, we found that some of the PDAC cell lines were
extremely inconsistent in invadopodia formation and
could not be relied upon for reproducible studies. Other
reports focus on one PDAC cell line examining specific
pathways [29, 30]. We have now identified two PDAC
cell lines that reproducibly potentiate significant invado-
podia activity and can be confidently used to further
studies in this area. With regards to invadopodia forma-
tion, the PDAC cell lines in this study were compared to
MDA-MB-231 cells – a breast cancer cell line that is
well known for its ability to form invadopodia. Consist-
ent with the findings for different PDAC lines, some
breast cancer cell lines are able to form invadopodia
(such as MDA-MB-231 or BT-549) [23, 31, 32] whereas
others are not (e.g. MCF-7) [33].
Using these cell lines we proceeded to investigate how
the TME might impact on invasive activity. The TME
has a particular role in PDAC – not only because the
major part of PDACs consists of fibroblast and mono-
cytes/macrophages [16] but also because there is a com-
plex interaction between monocytes/macrophages and
PDAC cells potentially modifying the invasive potential
of PDAC cells [17]. Monocytes and macrophages in the
TME appear to have both pro- and antitumor effects
which are suggested to be due to different cytokine pro-
files depending on the differentiation and polarization
[34, 35]. Most studies examining mononuclear cells as
part of the TME are focusing on macrophages [36, 37],
however, there is evidence that monocytes are present in
the TME of PDAC [16]. Nevertheless, the prognostic
value of monocyte infiltration of the PDAC TME has
not been extensively explored.
Taken together, the results of current studies suggest
that pro-inflammatory features of the TME determined
by the polarization and pro-inflammatory cytokine pro-
file leads to a more aggressive and invasive tumour be-
haviour and thus decreases prognosis.
This is the first study to show that monocyte-like cells –
which are an essential part of the TME [16] – have the
ability to reduce the formation of invadopodia in PDAC
cells and thus highly significantly decrease their invasive
migratory behavior, which would inhibit their metastatic
potential. Interestingly, THP-1 cells are able to degrade
the ECM and form invadopodia as well [38].
Our results indicate that the suppressive activity of undif-
ferentiated monocyte-like cells of the PDAC cells might be
mediated via secretion of TIMP2 but not TIMP1. This is
consistent with a report in breast cancer cells that sug-
gested TIMP2 suppressed invadopodia formation. How-
ever, in this study, activity was measured by positive
cortactin staining but not matrix degradation [13]. The spe-
cific inhibitory effect of TIMP2 might be due to the differ-
ential inhibition of TIMP1 and TIMP2. Indeed, MMP2,
MMP9, and MT1-MMP are considered the most important
MMPs needed for invadopodia activity [39]. MT1-MMP, a
membrane-bound MMP, has a key role not only degrading
the ECM but also activating of MMP2 [40] which in turn
activates MMP9 [41]. In contrast, TIMP1 inhibits soluble
MMPs and has a very low affinity to membrane-bound
MMPs such as MT1-MMP. Taken together, there is evi-
dence that the TIMP2-mediated inhibition of MT1-MMP
is the key to inhibiting invadopodia formation [42].
(See figure on previous page.)
Fig. 4 TIMP2 inhibits invadopodia formation in PDAC cells. a Representative images from a PaTu8902 invadopodia assay where the cells were
either incubated with THP1 conditioned medium (THP1-CM), or were cultured with recombinant TIMP1 (rTIMP1) or recombinant TIMP2 (rTIMP2)
at indicated concentrations. b and c Quantification of degradation per field of view for experimental conditions described above (a). d
Representative images from a CFPAC-1 invadopodia assay where the cells were either incubated with THP1 conditioned medium (THP1-CM), or
were cultured with recombinant TIMP1 (rTIMP1) or recombinant TIMP2 (rTIMP2) at indicated concentrations. e and f) Quantification of
degradation per field of view for experimental conditions described above (d). In all cases **** = p < 0.0001, ** = p < 0.01, *** = p < 0.001.
Experiments were repeated three times
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Fig. 5 (See legend on next page.)
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Nonetheless, we believe that there are other mechanisms
of how undifferentiated monocyte-like cells can inhibit
invadopodia formation as well since we found that a
monocyte-like cell/PDAC cell co-culture prior to the ac-
tual invadopodia assay was also able to reduce cancer cell
invasion (Fig. 1c and d). These mechanisms could include
transcriptional changes in the cancer cells, e.g. upregula-
tion of S100A8 and S100A9 which is known to increase
the invasive potential of cancer cells [43].
Interestingly, in human hepatocellular carcinoma (HCC)
samples, downregulation of TIMP2 expression was signifi-
cantly associated with liver invasion and poorer survival
outcomes [44]. Currently, PDAC tumours are considered
to be immunologically “cold” [45]. We would suggest that
an aspiration to increase the immune infiltrate in the PDAC
setting [46] should consider specifically increasing the pres-
ence of TIMP2 secreting monocyte-like cells.
We found that THP1 monocyte-like cells produce
TIMP2 in relevant concentrations without being co-
cultured with PDAC cells. THP1 CM is able to suppress
invadopodia formation, a direct interaction between
THP1 cells and PDAC cells is not necessary for this effect.
However, there is evidence that a direct co-culture of
mononuclear cells and cancer cells leads to changes both
in MMP and TIMP expression levels [47]. Besides the
examination of these interactions, further experiments
could also use human monocyte derived macrophages in
the stages of M0, M1, and M2 to see the differential effects
on invasion depending on the polarisation of the macro-
phages. To translate these findings into an in vivo model,
monocyte-like cells or differentiated macrophages could
be injected and isolated in nude/SCID mice.
Conclusions
In conclusion, our findings are indicative that TIMP2
could both be a potential prognostic marker and a thera-
peutic target in PDAC. A high ratio of TIMP2-secreting
monocyte-like cells could be associated with reduced
metastatic potential and better prognosis. Furthermore,
the application of synthetic TIMP2 agonists could pos-
sibly lead to a reduction of cancer cell invasion in vivo.
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Fig. 5 TIMP2-mediated inhibition of invadopodia is reversible after washout in pancreatic cancer cells. a Representative images from a PaTu8902
invadopodia assay where the cells were either incubated for 48 h with control medium, control medium with GM6001 (10 μM) washed out after
5 h and replaced with fresh control media or GM6001 (10 μM) left for 48 h. b Quantification of degradation per field of view for experimental
conditions described above (a). c Representative images from a PaTu8902 invadopodia assay where the cells were either incubated for 48 h with
control medium, control medium with recombinant TIMP2 (rTIMP2, 50 ng/ml) washed out after 5 h and replaced with fresh control medium or
control medium with rTIMP2 (50 ng/ml) left for 48 h. d Quantification of degradation per field of view for experimental conditions described
above (c). There was no significant difference in the amount of gelatin degradation between the control cells and the cells where rTIMP2 had
been removed post 5 h incubation indicating that PaTu8902 cells were able to recover invadopodia activity once rTIMP2 had been removed. In
contrast, again, those cells continuously exposed to rTIMP2 revealed significantly reduced invadopodia formation. e Representative images from a
CFPAC-1 invadopodia assay where the cells were either incubated for 48 h with control medium, control medium with GM6001 (10 μM) washed
out after 5 h and replaced with fresh control media or GM6001 (10 μM) left for 48 h. f Quantification of degradation per field of view for
experimental conditions described above (e). g Representative images from a CFPAC-1 invadopodia assay where the cells were either incubated
for 48 h with control medium, control medium with recombinant TIMP2 (rTIMP2, 50 ng/ml) washed out after 5 h and replaced with fresh control
media or rTIMP2 (50 ng/ml) left for 48 h. h Quantification of degradation per field of view for experimental conditions described above. In all
cases **** = p < 0.0001, *** = p < 0.001, ** = p < 0.01. Experiments were repeated three times
Table 2 MTT assay results of PaTu8902 cells with different
treatment conditions
mean % gain in growth standard deviation
G 52 12
G + SF 52 14
G + CM 52 12
G + rTIMP2 (50 ng/ml) 56 16
G = DMEM supplemented with 10% v/v fetal bovine serum (FBS) and 1mM
penicillin/streptomycin. SF = serum-free DMEM, CM = THP1 conditioned
medium, rTIMP2 = recombinant tissue inhibitor of metalloproteinases. ANOVA
of raw data reported no significant difference between any of the groups
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